nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2C19—Gefitinib—lung cancer	0.0603	0.124	CbGbCtD
Atomoxetine—CYP2C19—Teniposide—lung cancer	0.0585	0.12	CbGbCtD
Atomoxetine—CYP2D6—Gefitinib—lung cancer	0.0459	0.0942	CbGbCtD
Atomoxetine—CYP2D6—Vinorelbine—lung cancer	0.0353	0.0726	CbGbCtD
Atomoxetine—CYP3A4—Topotecan—lung cancer	0.0319	0.0655	CbGbCtD
Atomoxetine—CYP3A4—Gefitinib—lung cancer	0.0292	0.0599	CbGbCtD
Atomoxetine—CYP3A4—Teniposide—lung cancer	0.0283	0.0581	CbGbCtD
Atomoxetine—CYP2D6—Erlotinib—lung cancer	0.0271	0.0557	CbGbCtD
Atomoxetine—CYP3A4—Vinorelbine—lung cancer	0.0225	0.0461	CbGbCtD
Atomoxetine—CYP2D6—Vinblastine—lung cancer	0.0218	0.0447	CbGbCtD
Atomoxetine—CYP3A4—Crizotinib—lung cancer	0.0179	0.0367	CbGbCtD
Atomoxetine—CYP3A4—Erlotinib—lung cancer	0.0172	0.0354	CbGbCtD
Atomoxetine—CYP3A4—Paclitaxel—lung cancer	0.0158	0.0324	CbGbCtD
Atomoxetine—CYP3A4—Irinotecan—lung cancer	0.0156	0.032	CbGbCtD
Atomoxetine—CYP3A4—Vinblastine—lung cancer	0.0138	0.0284	CbGbCtD
Atomoxetine—CYP2D6—Doxorubicin—lung cancer	0.0134	0.0275	CbGbCtD
Atomoxetine—CYP3A4—Etoposide—lung cancer	0.0125	0.0256	CbGbCtD
Atomoxetine—CYP3A4—Docetaxel—lung cancer	0.0114	0.0234	CbGbCtD
Atomoxetine—HTR2A—phrenic nerve—lung cancer	0.00866	0.42	CbGeAlD
Atomoxetine—CYP3A4—Doxorubicin—lung cancer	0.00851	0.0175	CbGbCtD
Atomoxetine—HTR2A—pulmonary artery—lung cancer	0.00314	0.152	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—lung cancer	0.00141	0.202	CrCbGaD
Atomoxetine—NPY1R—lung—lung cancer	0.00138	0.0667	CbGeAlD
Atomoxetine—SLC6A3—respiratory system—lung cancer	0.00109	0.0529	CbGeAlD
Atomoxetine—SLC6A4—respiratory system—lung cancer	0.001	0.0484	CbGeAlD
Atomoxetine—NPY1R—lymph node—lung cancer	0.000941	0.0456	CbGeAlD
Atomoxetine—SLC6A2—respiratory system—lung cancer	0.00088	0.0426	CbGeAlD
Atomoxetine—Ketoprofen—CXCL8—lung cancer	0.000627	0.0899	CrCbGaD
Atomoxetine—SLC6A3—lung—lung cancer	0.000579	0.0281	CbGeAlD
Atomoxetine—SLC6A4—lung—lung cancer	0.000531	0.0257	CbGeAlD
Atomoxetine—HTR2A—respiratory system—lung cancer	0.000529	0.0256	CbGeAlD
Atomoxetine—SLC6A2—lung—lung cancer	0.000467	0.0226	CbGeAlD
Atomoxetine—HTR2A—epithelium—lung cancer	0.000442	0.0214	CbGeAlD
Atomoxetine—HTR2A—trachea—lung cancer	0.000391	0.0189	CbGeAlD
Atomoxetine—Warfarin—CYP1A1—lung cancer	0.000379	0.0544	CrCbGaD
Atomoxetine—Reboxetine—ABCB1—lung cancer	0.000352	0.0506	CrCbGaD
Atomoxetine—Protriptyline—ABCB1—lung cancer	0.000324	0.0464	CrCbGaD
Atomoxetine—SLC6A2—lymph node—lung cancer	0.00032	0.0155	CbGeAlD
Atomoxetine—Fenoprofen—PTGS2—lung cancer	0.00031	0.0444	CrCbGaD
Atomoxetine—HTR2A—lung—lung cancer	0.000281	0.0136	CbGeAlD
Atomoxetine—Fenoprofen—ALB—lung cancer	0.000276	0.0396	CrCbGaD
Atomoxetine—Desipramine—CYP2A6—lung cancer	0.000274	0.0393	CrCbGaD
Atomoxetine—Propranolol—CYP1A1—lung cancer	0.000254	0.0364	CrCbGaD
Atomoxetine—Shock—Paclitaxel—lung cancer	0.000243	0.000771	CcSEcCtD
Atomoxetine—Dizziness—Vinorelbine—lung cancer	0.000243	0.00077	CcSEcCtD
Atomoxetine—Abdominal pain upper—Doxorubicin—lung cancer	0.000243	0.00077	CcSEcCtD
Atomoxetine—Nervous system disorder—Paclitaxel—lung cancer	0.000242	0.000768	CcSEcCtD
Atomoxetine—Tachycardia—Paclitaxel—lung cancer	0.000241	0.000765	CcSEcCtD
Atomoxetine—Breast disorder—Doxorubicin—lung cancer	0.00024	0.000762	CcSEcCtD
Atomoxetine—Anorexia—Etoposide—lung cancer	0.00024	0.000762	CcSEcCtD
Atomoxetine—Skin disorder—Paclitaxel—lung cancer	0.00024	0.000761	CcSEcCtD
Atomoxetine—Abdominal pain—Irinotecan—lung cancer	0.000239	0.000759	CcSEcCtD
Atomoxetine—Body temperature increased—Irinotecan—lung cancer	0.000239	0.000759	CcSEcCtD
Atomoxetine—Decreased appetite—Cisplatin—lung cancer	0.000239	0.000758	CcSEcCtD
Atomoxetine—Hyperhidrosis—Paclitaxel—lung cancer	0.000239	0.000757	CcSEcCtD
Atomoxetine—Phenprocoumon—ALB—lung cancer	0.000238	0.0341	CrCbGaD
Atomoxetine—Nasopharyngitis—Doxorubicin—lung cancer	0.000238	0.000754	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000237	0.000753	CcSEcCtD
Atomoxetine—Nortriptyline—CYP2E1—lung cancer	0.000237	0.0339	CrCbGaD
Atomoxetine—Infestation NOS—Methotrexate—lung cancer	0.000236	0.00075	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—lung cancer	0.000236	0.00075	CcSEcCtD
Atomoxetine—Depression—Methotrexate—lung cancer	0.000236	0.000748	CcSEcCtD
Atomoxetine—Anorexia—Paclitaxel—lung cancer	0.000235	0.000747	CcSEcCtD
Atomoxetine—Pain—Cisplatin—lung cancer	0.000235	0.000746	CcSEcCtD
Atomoxetine—Vomiting—Vinorelbine—lung cancer	0.000233	0.000741	CcSEcCtD
Atomoxetine—Body temperature increased—Gemcitabine—lung cancer	0.000233	0.00074	CcSEcCtD
Atomoxetine—Fluoxetine—ALB—lung cancer	0.000232	0.0332	CrCbGaD
Atomoxetine—Rash—Vinorelbine—lung cancer	0.000231	0.000734	CcSEcCtD
Atomoxetine—Dermatitis—Vinorelbine—lung cancer	0.000231	0.000734	CcSEcCtD
Atomoxetine—Headache—Vinorelbine—lung cancer	0.00023	0.00073	CcSEcCtD
Atomoxetine—Syncope—Docetaxel—lung cancer	0.00023	0.00073	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—lung cancer	0.00023	0.000729	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—lung cancer	0.00023	0.000729	CcSEcCtD
Atomoxetine—Palpitations—Docetaxel—lung cancer	0.000227	0.000719	CcSEcCtD
Atomoxetine—Feeling abnormal—Cisplatin—lung cancer	0.000226	0.000719	CcSEcCtD
Atomoxetine—Paraesthesia—Etoposide—lung cancer	0.000226	0.000717	CcSEcCtD
Atomoxetine—Loss of consciousness—Docetaxel—lung cancer	0.000225	0.000715	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000225	0.000714	CcSEcCtD
Atomoxetine—Somnolence—Etoposide—lung cancer	0.000224	0.00071	CcSEcCtD
Atomoxetine—Cough—Docetaxel—lung cancer	0.000224	0.00071	CcSEcCtD
Atomoxetine—Insomnia—Paclitaxel—lung cancer	0.000223	0.000709	CcSEcCtD
Atomoxetine—Convulsion—Docetaxel—lung cancer	0.000222	0.000705	CcSEcCtD
Atomoxetine—Paraesthesia—Paclitaxel—lung cancer	0.000222	0.000703	CcSEcCtD
Atomoxetine—Fluoxetine—ABCB1—lung cancer	0.000221	0.0317	CrCbGaD
Atomoxetine—Somnolence—Paclitaxel—lung cancer	0.000219	0.000696	CcSEcCtD
Atomoxetine—Decreased appetite—Etoposide—lung cancer	0.000219	0.000695	CcSEcCtD
Atomoxetine—Chest pain—Docetaxel—lung cancer	0.000218	0.000693	CcSEcCtD
Atomoxetine—Arthralgia—Docetaxel—lung cancer	0.000218	0.000693	CcSEcCtD
Atomoxetine—Myalgia—Docetaxel—lung cancer	0.000218	0.000693	CcSEcCtD
Atomoxetine—Nausea—Vinorelbine—lung cancer	0.000218	0.000692	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Etoposide—lung cancer	0.000217	0.00069	CcSEcCtD
Atomoxetine—Dyspepsia—Paclitaxel—lung cancer	0.000217	0.00069	CcSEcCtD
Atomoxetine—Body temperature increased—Cisplatin—lung cancer	0.000217	0.000689	CcSEcCtD
Atomoxetine—Asthenia—Irinotecan—lung cancer	0.000217	0.000689	CcSEcCtD
Atomoxetine—Fatigue—Etoposide—lung cancer	0.000217	0.000689	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000217	0.000688	CcSEcCtD
Atomoxetine—Constipation—Etoposide—lung cancer	0.000215	0.000683	CcSEcCtD
Atomoxetine—Pain—Etoposide—lung cancer	0.000215	0.000683	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—lung cancer	0.000215	0.000681	CcSEcCtD
Atomoxetine—Decreased appetite—Paclitaxel—lung cancer	0.000215	0.000681	CcSEcCtD
Atomoxetine—Dry mouth—Docetaxel—lung cancer	0.000213	0.000677	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000213	0.000677	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000213	0.000676	CcSEcCtD
Atomoxetine—Fatigue—Paclitaxel—lung cancer	0.000213	0.000675	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—lung cancer	0.000212	0.000673	CcSEcCtD
Atomoxetine—Asthenia—Gemcitabine—lung cancer	0.000212	0.000671	CcSEcCtD
Atomoxetine—Warfarin—ALB—lung cancer	0.000211	0.0303	CrCbGaD
Atomoxetine—Pain—Paclitaxel—lung cancer	0.000211	0.00067	CcSEcCtD
Atomoxetine—Constipation—Paclitaxel—lung cancer	0.000211	0.00067	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—lung cancer	0.00021	0.000665	CcSEcCtD
Atomoxetine—Pruritus—Gemcitabine—lung cancer	0.000209	0.000662	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—lung cancer	0.000208	0.00066	CcSEcCtD
Atomoxetine—Infection—Docetaxel—lung cancer	0.000208	0.00066	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—lung cancer	0.000208	0.000659	CcSEcCtD
Atomoxetine—Feeling abnormal—Etoposide—lung cancer	0.000207	0.000658	CcSEcCtD
Atomoxetine—Diarrhoea—Irinotecan—lung cancer	0.000207	0.000657	CcSEcCtD
Atomoxetine—Orphenadrine—CYP2E1—lung cancer	0.000207	0.0297	CrCbGaD
Atomoxetine—Maprotiline—ABCB1—lung cancer	0.000206	0.0296	CrCbGaD
Atomoxetine—Gastrointestinal pain—Etoposide—lung cancer	0.000206	0.000653	CcSEcCtD
Atomoxetine—Shock—Docetaxel—lung cancer	0.000206	0.000653	CcSEcCtD
Atomoxetine—Nervous system disorder—Docetaxel—lung cancer	0.000205	0.000651	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—lung cancer	0.000205	0.00065	CcSEcCtD
Atomoxetine—Infestation NOS—Doxorubicin—lung cancer	0.000205	0.00065	CcSEcCtD
Atomoxetine—Tachycardia—Docetaxel—lung cancer	0.000204	0.000648	CcSEcCtD
Atomoxetine—Feeling abnormal—Paclitaxel—lung cancer	0.000203	0.000646	CcSEcCtD
Atomoxetine—Skin disorder—Docetaxel—lung cancer	0.000203	0.000645	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000202	0.000641	CcSEcCtD
Atomoxetine—Diarrhoea—Gemcitabine—lung cancer	0.000202	0.00064	CcSEcCtD
Atomoxetine—Dizziness—Irinotecan—lung cancer	0.0002	0.000635	CcSEcCtD
Atomoxetine—Urticaria—Etoposide—lung cancer	0.0002	0.000635	CcSEcCtD
Atomoxetine—Anorexia—Docetaxel—lung cancer	0.000199	0.000633	CcSEcCtD
Atomoxetine—Body temperature increased—Etoposide—lung cancer	0.000199	0.000632	CcSEcCtD
Atomoxetine—Abdominal pain—Etoposide—lung cancer	0.000199	0.000632	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—lung cancer	0.000199	0.000632	CcSEcCtD
Atomoxetine—Asthenia—Cisplatin—lung cancer	0.000197	0.000626	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—lung cancer	0.000197	0.000625	CcSEcCtD
Atomoxetine—Propafenone—ABCB1—lung cancer	0.000197	0.0283	CrCbGaD
Atomoxetine—Urticaria—Paclitaxel—lung cancer	0.000196	0.000622	CcSEcCtD
Atomoxetine—Body temperature increased—Paclitaxel—lung cancer	0.000195	0.000619	CcSEcCtD
Atomoxetine—Abdominal pain—Paclitaxel—lung cancer	0.000195	0.000619	CcSEcCtD
Atomoxetine—Desipramine—CYP2E1—lung cancer	0.000195	0.0279	CrCbGaD
Atomoxetine—Angiopathy—Methotrexate—lung cancer	0.000193	0.000611	CcSEcCtD
Atomoxetine—Vomiting—Irinotecan—lung cancer	0.000192	0.000611	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—lung cancer	0.000192	0.00061	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—lung cancer	0.000191	0.000607	CcSEcCtD
Atomoxetine—Rash—Irinotecan—lung cancer	0.000191	0.000606	CcSEcCtD
Atomoxetine—Dermatitis—Irinotecan—lung cancer	0.000191	0.000605	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000191	0.000605	CcSEcCtD
Atomoxetine—Chills—Methotrexate—lung cancer	0.00019	0.000604	CcSEcCtD
Atomoxetine—Headache—Irinotecan—lung cancer	0.00019	0.000602	CcSEcCtD
Atomoxetine—Insomnia—Docetaxel—lung cancer	0.000189	0.000601	CcSEcCtD
Atomoxetine—Diarrhoea—Cisplatin—lung cancer	0.000188	0.000597	CcSEcCtD
Atomoxetine—Paraesthesia—Docetaxel—lung cancer	0.000188	0.000596	CcSEcCtD
Atomoxetine—Vomiting—Gemcitabine—lung cancer	0.000187	0.000595	CcSEcCtD
Atomoxetine—Somnolence—Docetaxel—lung cancer	0.000186	0.00059	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—lung cancer	0.000186	0.00059	CcSEcCtD
Atomoxetine—Rash—Gemcitabine—lung cancer	0.000186	0.00059	CcSEcCtD
Atomoxetine—Dermatitis—Gemcitabine—lung cancer	0.000186	0.000589	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—lung cancer	0.000185	0.000586	CcSEcCtD
Atomoxetine—Headache—Gemcitabine—lung cancer	0.000185	0.000586	CcSEcCtD
Atomoxetine—Dyspepsia—Docetaxel—lung cancer	0.000184	0.000585	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—lung cancer	0.000183	0.0262	CrCbGaD
Atomoxetine—Hypoaesthesia—Doxorubicin—lung cancer	0.000183	0.00058	CcSEcCtD
Atomoxetine—Decreased appetite—Docetaxel—lung cancer	0.000182	0.000577	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—lung cancer	0.000181	0.000576	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—lung cancer	0.000181	0.000574	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000181	0.000573	CcSEcCtD
Atomoxetine—Asthenia—Etoposide—lung cancer	0.000181	0.000573	CcSEcCtD
Atomoxetine—Fatigue—Docetaxel—lung cancer	0.00018	0.000573	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—lung cancer	0.00018	0.000572	CcSEcCtD
Atomoxetine—Nausea—Irinotecan—lung cancer	0.00018	0.000571	CcSEcCtD
Atomoxetine—Pain—Docetaxel—lung cancer	0.000179	0.000568	CcSEcCtD
Atomoxetine—Constipation—Docetaxel—lung cancer	0.000179	0.000568	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—lung cancer	0.000179	0.000567	CcSEcCtD
Atomoxetine—Pruritus—Etoposide—lung cancer	0.000178	0.000565	CcSEcCtD
Atomoxetine—Asthenia—Paclitaxel—lung cancer	0.000177	0.000562	CcSEcCtD
Atomoxetine—Nausea—Gemcitabine—lung cancer	0.000175	0.000556	CcSEcCtD
Atomoxetine—Vomiting—Cisplatin—lung cancer	0.000175	0.000555	CcSEcCtD
Atomoxetine—Pruritus—Paclitaxel—lung cancer	0.000175	0.000554	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—lung cancer	0.000174	0.000553	CcSEcCtD
Atomoxetine—Rash—Cisplatin—lung cancer	0.000173	0.00055	CcSEcCtD
Atomoxetine—Dermatitis—Cisplatin—lung cancer	0.000173	0.000549	CcSEcCtD
Atomoxetine—Feeling abnormal—Docetaxel—lung cancer	0.000172	0.000547	CcSEcCtD
Atomoxetine—Diarrhoea—Etoposide—lung cancer	0.000172	0.000547	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Docetaxel—lung cancer	0.000171	0.000543	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—lung cancer	0.000171	0.000541	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—lung cancer	0.000171	0.000541	CcSEcCtD
Atomoxetine—Diarrhoea—Paclitaxel—lung cancer	0.000169	0.000536	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—lung cancer	0.000167	0.000529	CcSEcCtD
Atomoxetine—Dizziness—Etoposide—lung cancer	0.000166	0.000528	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—lung cancer	0.000166	0.000527	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—lung cancer	0.000166	0.000526	CcSEcCtD
Atomoxetine—Abdominal pain—Docetaxel—lung cancer	0.000165	0.000525	CcSEcCtD
Atomoxetine—Body temperature increased—Docetaxel—lung cancer	0.000165	0.000525	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—lung cancer	0.000165	0.000523	CcSEcCtD
Atomoxetine—Dizziness—Paclitaxel—lung cancer	0.000163	0.000518	CcSEcCtD
Atomoxetine—Nausea—Cisplatin—lung cancer	0.000163	0.000518	CcSEcCtD
Atomoxetine—Ketoprofen—ALB—lung cancer	0.000163	0.0234	CrCbGaD
Atomoxetine—Cough—Methotrexate—lung cancer	0.000161	0.000512	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—lung cancer	0.000161	0.000511	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—lung cancer	0.00016	0.000508	CcSEcCtD
Atomoxetine—Vomiting—Etoposide—lung cancer	0.00016	0.000508	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—lung cancer	0.00016	0.000508	CcSEcCtD
Atomoxetine—Rash—Etoposide—lung cancer	0.000159	0.000504	CcSEcCtD
Atomoxetine—Dermatitis—Etoposide—lung cancer	0.000159	0.000503	CcSEcCtD
Atomoxetine—Headache—Etoposide—lung cancer	0.000158	0.000501	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—lung cancer	0.000158	0.0005	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—lung cancer	0.000157	0.000499	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—lung cancer	0.000157	0.000499	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—lung cancer	0.000157	0.000499	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—lung cancer	0.000157	0.000498	CcSEcCtD
Atomoxetine—Vomiting—Paclitaxel—lung cancer	0.000157	0.000498	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—lung cancer	0.000157	0.000497	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000156	0.000496	CcSEcCtD
Atomoxetine—Rash—Paclitaxel—lung cancer	0.000156	0.000494	CcSEcCtD
Atomoxetine—Dermatitis—Paclitaxel—lung cancer	0.000155	0.000494	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—lung cancer	0.000155	0.000493	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—lung cancer	0.000155	0.000491	CcSEcCtD
Atomoxetine—Headache—Paclitaxel—lung cancer	0.000155	0.000491	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—lung cancer	0.000154	0.000488	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—lung cancer	0.000151	0.000479	CcSEcCtD
Atomoxetine—Asthenia—Docetaxel—lung cancer	0.00015	0.000476	CcSEcCtD
Atomoxetine—Infection—Methotrexate—lung cancer	0.00015	0.000475	CcSEcCtD
Atomoxetine—Nausea—Etoposide—lung cancer	0.00015	0.000475	CcSEcCtD
Atomoxetine—Pruritus—Docetaxel—lung cancer	0.000148	0.00047	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—lung cancer	0.000148	0.000469	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—lung cancer	0.000147	0.000467	CcSEcCtD
Atomoxetine—Nausea—Paclitaxel—lung cancer	0.000147	0.000465	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—lung cancer	0.000146	0.000465	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—lung cancer	0.000146	0.000463	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—lung cancer	0.000144	0.000456	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—lung cancer	0.000144	0.000456	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—lung cancer	0.000143	0.000455	CcSEcCtD
Atomoxetine—Diarrhoea—Docetaxel—lung cancer	0.000143	0.000454	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—lung cancer	0.000141	0.000449	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—lung cancer	0.000141	0.000446	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—lung cancer	0.00014	0.000443	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—lung cancer	0.000139	0.00044	CcSEcCtD
Atomoxetine—Dizziness—Docetaxel—lung cancer	0.000138	0.000439	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000137	0.000436	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—lung cancer	0.000136	0.000433	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—lung cancer	0.000136	0.000432	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—lung cancer	0.000136	0.000432	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—lung cancer	0.000136	0.000432	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—lung cancer	0.000136	0.000431	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—lung cancer	0.000135	0.00043	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000135	0.000429	CcSEcCtD
Atomoxetine—Propranolol—ABCB1—lung cancer	0.000135	0.0193	CrCbGaD
Atomoxetine—Somnolence—Methotrexate—lung cancer	0.000134	0.000425	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—lung cancer	0.000133	0.000423	CcSEcCtD
Atomoxetine—Vomiting—Docetaxel—lung cancer	0.000133	0.000422	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—lung cancer	0.000133	0.000421	CcSEcCtD
Atomoxetine—Rash—Docetaxel—lung cancer	0.000132	0.000419	CcSEcCtD
Atomoxetine—Dermatitis—Docetaxel—lung cancer	0.000132	0.000418	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—lung cancer	0.000131	0.000416	CcSEcCtD
Atomoxetine—Headache—Docetaxel—lung cancer	0.000131	0.000416	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—lung cancer	0.00013	0.000413	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—lung cancer	0.00013	0.000413	CcSEcCtD
Atomoxetine—Nortriptyline—ALB—lung cancer	0.00013	0.0186	CrCbGaD
Atomoxetine—Infection—Doxorubicin—lung cancer	0.00013	0.000412	CcSEcCtD
Atomoxetine—Pain—Methotrexate—lung cancer	0.000129	0.000409	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—lung cancer	0.000128	0.000408	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—lung cancer	0.000128	0.000406	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—lung cancer	0.000127	0.000404	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—lung cancer	0.000127	0.000403	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—lung cancer	0.000126	0.000401	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—lung cancer	0.000124	0.000395	CcSEcCtD
Atomoxetine—Nausea—Docetaxel—lung cancer	0.000124	0.000394	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—lung cancer	0.000124	0.000394	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—lung cancer	0.000123	0.000391	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—lung cancer	0.00012	0.00038	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—lung cancer	0.000119	0.000378	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—lung cancer	0.000119	0.000378	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000119	0.000378	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—lung cancer	0.000118	0.000375	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—lung cancer	0.000117	0.000372	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—lung cancer	0.000116	0.000368	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—lung cancer	0.000115	0.000365	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—lung cancer	0.000113	0.00036	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000113	0.000358	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—lung cancer	0.000113	0.000357	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—lung cancer	0.000112	0.000354	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—lung cancer	0.000112	0.000354	CcSEcCtD
Atomoxetine—Methadone—ABCB1—lung cancer	0.000111	0.0159	CrCbGaD
Atomoxetine—Asthenia—Methotrexate—lung cancer	0.000108	0.000343	CcSEcCtD
Atomoxetine—Feeling abnormal—Doxorubicin—lung cancer	0.000108	0.000342	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—lung cancer	0.000107	0.000339	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—lung cancer	0.000107	0.000339	CcSEcCtD
Atomoxetine—Urticaria—Doxorubicin—lung cancer	0.000104	0.000329	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—lung cancer	0.000103	0.000328	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—lung cancer	0.000103	0.000328	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—lung cancer	0.000103	0.000327	CcSEcCtD
Atomoxetine—Desipramine—ABCB1—lung cancer	0.000102	0.0146	CrCbGaD
Atomoxetine—Dizziness—Methotrexate—lung cancer	9.97e-05	0.000316	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—lung cancer	9.59e-05	0.000304	CcSEcCtD
Atomoxetine—Rash—Methotrexate—lung cancer	9.51e-05	0.000302	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—lung cancer	9.5e-05	0.000301	CcSEcCtD
Atomoxetine—Headache—Methotrexate—lung cancer	9.45e-05	0.0003	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—lung cancer	9.37e-05	0.000297	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—lung cancer	9.24e-05	0.000293	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—lung cancer	8.96e-05	0.000284	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—lung cancer	8.93e-05	0.000284	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—lung cancer	8.63e-05	0.000274	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—lung cancer	8.3e-05	0.000263	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—lung cancer	8.23e-05	0.000261	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—lung cancer	8.22e-05	0.000261	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—lung cancer	8.18e-05	0.00026	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—lung cancer	7.76e-05	0.000246	CcSEcCtD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—lung cancer	1.26e-05	7.39e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KIT—lung cancer	1.26e-05	7.39e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—NRAS—lung cancer	1.26e-05	7.39e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL8—lung cancer	1.26e-05	7.39e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.25e-05	7.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNG11—lung cancer	1.25e-05	7.35e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—lung cancer	1.25e-05	7.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL8—lung cancer	1.25e-05	7.33e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGF—lung cancer	1.24e-05	7.3e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—lung cancer	1.24e-05	7.28e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HIF1A—lung cancer	1.24e-05	7.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—lung cancer	1.24e-05	7.25e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—STK11—lung cancer	1.23e-05	7.2e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—lung cancer	1.22e-05	7.18e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—lung cancer	1.22e-05	7.13e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—lung cancer	1.22e-05	7.13e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—lung cancer	1.21e-05	7.08e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK3—lung cancer	1.21e-05	7.07e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—lung cancer	1.21e-05	7.07e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—lung cancer	1.2e-05	7.06e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAT—lung cancer	1.2e-05	7.05e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—lung cancer	1.2e-05	7.03e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOA1—lung cancer	1.2e-05	7.03e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—lung cancer	1.2e-05	7.02e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—lung cancer	1.2e-05	7.01e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.2e-05	7.01e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—lung cancer	1.19e-05	7e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDOA—lung cancer	1.19e-05	7e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—lung cancer	1.19e-05	6.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KDR—lung cancer	1.19e-05	6.96e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—lung cancer	1.18e-05	6.94e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—lung cancer	1.18e-05	6.93e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—lung cancer	1.17e-05	6.88e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—lung cancer	1.17e-05	6.87e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—JUN—lung cancer	1.17e-05	6.87e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—lung cancer	1.17e-05	6.86e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6R—lung cancer	1.17e-05	6.86e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—lung cancer	1.17e-05	6.86e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CREBBP—lung cancer	1.17e-05	6.85e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—lung cancer	1.16e-05	6.83e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—lung cancer	1.16e-05	6.82e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—JUN—lung cancer	1.16e-05	6.81e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOA3—lung cancer	1.16e-05	6.79e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TYMS—lung cancer	1.15e-05	6.74e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—lung cancer	1.15e-05	6.73e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—lung cancer	1.14e-05	6.69e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—lung cancer	1.14e-05	6.68e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JUN—lung cancer	1.14e-05	6.67e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—lung cancer	1.14e-05	6.66e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—lung cancer	1.14e-05	6.66e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1A—lung cancer	1.13e-05	6.66e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—lung cancer	1.13e-05	6.64e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—lung cancer	1.13e-05	6.63e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCG2—lung cancer	1.13e-05	6.61e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADCY1—lung cancer	1.13e-05	6.61e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1A—lung cancer	1.13e-05	6.61e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—lung cancer	1.12e-05	6.59e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAP2K1—lung cancer	1.11e-05	6.54e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CD—lung cancer	1.11e-05	6.49e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—lung cancer	1.11e-05	6.49e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAT—lung cancer	1.11e-05	6.48e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO2—lung cancer	1.11e-05	6.48e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HPGDS—lung cancer	1.11e-05	6.48e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—lung cancer	1.1e-05	6.48e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1A—lung cancer	1.1e-05	6.47e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—lung cancer	1.1e-05	6.45e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.1e-05	6.44e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—lung cancer	1.1e-05	6.43e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—lung cancer	1.1e-05	6.43e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—lung cancer	1.09e-05	6.41e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KIT—lung cancer	1.09e-05	6.41e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APC—lung cancer	1.09e-05	6.41e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—NRAS—lung cancer	1.09e-05	6.41e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—lung cancer	1.08e-05	6.36e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGF—lung cancer	1.08e-05	6.34e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EP300—lung cancer	1.08e-05	6.33e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A1—lung cancer	1.08e-05	6.31e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—lung cancer	1.08e-05	6.31e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—lung cancer	1.07e-05	6.3e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—lung cancer	1.07e-05	6.29e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EP300—lung cancer	1.07e-05	6.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ERCC2—lung cancer	1.07e-05	6.26e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GCLC—lung cancer	1.06e-05	6.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2A6—lung cancer	1.06e-05	6.21e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TYMS—lung cancer	1.06e-05	6.2e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SRC—lung cancer	1.05e-05	6.16e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EP300—lung cancer	1.05e-05	6.15e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK3—lung cancer	1.05e-05	6.14e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—lung cancer	1.04e-05	6.12e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SRC—lung cancer	1.04e-05	6.11e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—lung cancer	1.04e-05	6.11e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—lung cancer	1.03e-05	6.03e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—lung cancer	1.02e-05	6e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SRC—lung cancer	1.02e-05	5.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6R—lung cancer	1.02e-05	5.96e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—lung cancer	1.02e-05	5.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CREBBP—lung cancer	1.01e-05	5.95e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—lung cancer	1.01e-05	5.94e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRAS—lung cancer	1.01e-05	5.92e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—lung cancer	1.01e-05	5.89e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO1—lung cancer	1e-05	5.89e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRAS—lung cancer	1e-05	5.88e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—lung cancer	9.96e-06	5.84e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—lung cancer	9.96e-06	5.84e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—lung cancer	9.94e-06	5.83e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MDM2—lung cancer	9.92e-06	5.82e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A1—lung cancer	9.9e-06	5.81e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RAF1—lung cancer	9.88e-06	5.8e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—lung cancer	9.84e-06	5.77e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ERCC2—lung cancer	9.82e-06	5.76e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRAS—lung cancer	9.82e-06	5.76e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—lung cancer	9.78e-06	5.73e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAP2K1—lung cancer	9.68e-06	5.68e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK3—lung cancer	9.68e-06	5.67e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MTOR—lung cancer	9.65e-06	5.66e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CB—lung cancer	9.65e-06	5.66e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CD—lung cancer	9.61e-06	5.64e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK3—lung cancer	9.6e-06	5.63e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—lung cancer	9.52e-06	5.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—lung cancer	9.41e-06	5.52e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—lung cancer	9.41e-06	5.52e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK3—lung cancer	9.4e-06	5.51e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—lung cancer	9.34e-06	5.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—lung cancer	9.27e-06	5.44e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOA1—lung cancer	9.23e-06	5.42e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—lung cancer	9.21e-06	5.4e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—lung cancer	9.2e-06	5.4e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—lung cancer	9.14e-06	5.36e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—lung cancer	9.13e-06	5.36e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP2E1—lung cancer	9.01e-06	5.28e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—lung cancer	8.96e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—lung cancer	8.94e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NQO1—lung cancer	8.91e-06	5.22e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—lung cancer	8.88e-06	5.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—lung cancer	8.86e-06	5.2e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.84e-06	5.19e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—lung cancer	8.82e-06	5.17e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—lung cancer	8.7e-06	5.1e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	8.65e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—lung cancer	8.64e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—lung cancer	8.63e-06	5.06e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUN—lung cancer	8.62e-06	5.06e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MDM2—lung cancer	8.61e-06	5.05e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RAF1—lung cancer	8.58e-06	5.03e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOA1—lung cancer	8.49e-06	4.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—lung cancer	8.49e-06	4.98e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—lung cancer	8.45e-06	4.96e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—lung cancer	8.43e-06	4.94e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—lung cancer	8.39e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CB—lung cancer	8.38e-06	4.91e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MTOR—lung cancer	8.38e-06	4.91e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1A—lung cancer	8.36e-06	4.9e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—lung cancer	8.34e-06	4.89e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—lung cancer	8.14e-06	4.77e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—lung cancer	8.05e-06	4.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—STK11—lung cancer	8.03e-06	4.71e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—lung cancer	8.02e-06	4.71e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—lung cancer	8e-06	4.69e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—lung cancer	7.99e-06	4.68e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EP300—lung cancer	7.95e-06	4.66e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—lung cancer	7.93e-06	4.65e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CREBBP—lung cancer	7.82e-06	4.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—lung cancer	7.78e-06	4.56e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—lung cancer	7.76e-06	4.55e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—lung cancer	7.75e-06	4.55e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SRC—lung cancer	7.73e-06	4.54e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—lung cancer	7.73e-06	4.53e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—lung cancer	7.71e-06	4.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—lung cancer	7.7e-06	4.51e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—lung cancer	7.67e-06	4.5e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—lung cancer	7.66e-06	4.49e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—lung cancer	7.53e-06	4.42e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—lung cancer	7.51e-06	4.4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—lung cancer	7.5e-06	4.4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUN—lung cancer	7.49e-06	4.39e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—lung cancer	7.46e-06	4.37e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRAS—lung cancer	7.44e-06	4.36e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—lung cancer	7.43e-06	4.36e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CD—lung cancer	7.41e-06	4.35e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—lung cancer	7.39e-06	4.33e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—lung cancer	7.38e-06	4.33e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—lung cancer	7.33e-06	4.3e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—lung cancer	7.32e-06	4.29e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—lung cancer	7.28e-06	4.27e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	7.26e-06	4.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—lung cancer	7.24e-06	4.25e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAT—lung cancer	7.23e-06	4.24e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CREBBP—lung cancer	7.19e-06	4.22e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—lung cancer	7.18e-06	4.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK3—lung cancer	7.13e-06	4.18e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—lung cancer	7.07e-06	4.15e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—lung cancer	7.06e-06	4.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—lung cancer	7.03e-06	4.12e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—lung cancer	7.02e-06	4.12e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—lung cancer	6.93e-06	4.06e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TYMS—lung cancer	6.91e-06	4.05e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EP300—lung cancer	6.91e-06	4.05e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—lung cancer	6.87e-06	4.03e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—lung cancer	6.83e-06	4e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CD—lung cancer	6.82e-06	4e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—lung cancer	6.78e-06	3.98e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—lung cancer	6.73e-06	3.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SRC—lung cancer	6.72e-06	3.94e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—lung cancer	6.54e-06	3.84e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—lung cancer	6.53e-06	3.83e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—lung cancer	6.48e-06	3.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—lung cancer	6.48e-06	3.8e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A1—lung cancer	6.47e-06	3.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRAS—lung cancer	6.46e-06	3.79e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CB—lung cancer	6.46e-06	3.79e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ERCC2—lung cancer	6.42e-06	3.76e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—lung cancer	6.4e-06	3.76e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—lung cancer	6.4e-06	3.75e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—lung cancer	6.34e-06	3.72e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK3—lung cancer	6.19e-06	3.63e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—lung cancer	6.02e-06	3.53e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CB—lung cancer	5.94e-06	3.48e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—lung cancer	5.89e-06	3.45e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—lung cancer	5.89e-06	3.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	5.88e-06	3.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—lung cancer	5.69e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—lung cancer	5.58e-06	3.27e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—lung cancer	5.56e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOA1—lung cancer	5.55e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—lung cancer	5.44e-06	3.19e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—EP300—lung cancer	5.32e-06	3.12e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—lung cancer	5.21e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—lung cancer	5.13e-06	3.01e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	5.11e-06	3e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—lung cancer	5.07e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—lung cancer	4.94e-06	2.9e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—EP300—lung cancer	4.9e-06	2.87e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—lung cancer	4.83e-06	2.83e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—lung cancer	4.81e-06	2.82e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—lung cancer	4.73e-06	2.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CREBBP—lung cancer	4.7e-06	2.76e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—lung cancer	4.52e-06	2.65e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CD—lung cancer	4.46e-06	2.61e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—lung cancer	4.4e-06	2.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—lung cancer	4.17e-06	2.45e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—lung cancer	3.94e-06	2.31e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CB—lung cancer	3.88e-06	2.28e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—lung cancer	3.85e-06	2.26e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—lung cancer	3.62e-06	2.12e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—lung cancer	3.36e-06	1.97e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—lung cancer	3.22e-06	1.89e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—EP300—lung cancer	3.2e-06	1.88e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—lung cancer	2.96e-06	1.74e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—lung cancer	2.37e-06	1.39e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—lung cancer	1.93e-06	1.13e-05	CbGpPWpGaD
